627
Participants
Start Date
August 10, 2015
Primary Completion Date
September 12, 2017
Study Completion Date
September 12, 2017
BGF MDI 320/14.4/9.6 μg
Budesonide, Glycopyrronium, and Formoterol Fumarate
GFF MDI 14.4/9.6 μg
Glycopyrronium and Formoterol Fumarate
BFF MDI 320/9.6 μg
Budesonide and Formoterol Fumarate
Research Site, Richmond
Research Site, Richmond
Research Site, Newport News
Research Site, Abingdon
Research Site, Morgantown
Research Site, Winston-Salem
Research Site, Greensboro
Research Site, Gastonia
Research Site, Mooresville
Research Site, Charlotte
Research Site, Wilmington
Research Site, Hendersonville
Research Site, Spartanburg
Research Site, Union
Research Site, Charleston
Research Site, Mt. Pleasant
Research Site, Greenville
Research Site, Anderson
Research Site, Easley
Research Site, Seneca
Research Site, Old Point Station
Research Site, Rock Hill
Research Site, Dacula
Research Site, Norcross
Research Site, Rincon
Research Site, Ormond Beach
Research Site, Pensacola
Research Site, Winter Park
Research Site, Miami
Research Site, Tamarac
Research Site, Tampa
Research Site, Clearwater
Research Site, Jasper
Research Site, Dothan
Research Site, Johnson City
Research Site, Dublin
Research Site, Columbus
Research Site, Columbus
Research Site, Cincinnati
Research Site, Cincinnati
Research Site, Cincinnati
Research Site, Dayton
Research Site, Woodbury
Research Site, Minneapolis
Research Site, Minneapolis
Research Site, Edina
Research Site, St Louis
Research Site, Saint Charles
Research Site, Oklahoma City
Research Site, Longview
Research Site, Kingwood
Research Site, San Antonio
Research Site, Phoenix
Research Site, Peoria
Research Site, Albuquerque
Research Site, Las Vegas
Research Site, Reno
Research Site, Rolling Hills Estates
Research Site, Poway
Research Site, Fullerton
Research Site, Gold River
Research Site, Sacramento
Research Site, Medford
Research Site, Tacoma
Lead Sponsor
Pearl Therapeutics, Inc.
INDUSTRY